InvestorsHub Logo
Followers 69
Posts 7941
Boards Moderated 0
Alias Born 01/29/2015

Re: None

Thursday, 07/01/2021 10:41:48 PM

Thursday, July 01, 2021 10:41:48 PM

Post# of 16706
Yo 55. Can you offer a plausible reason why the CEO would deal with a supplier who would restrict the companies ability to conduct it's clinical trials in any country they so choose? Can you also offer up a coherent rationale for what supplier coughed up pills for the company to conduct clinical trials in other countries for COVID-19 but another supplier wouldn't risk another study of less likely to die patient for IPF/CC? Would it most likely be the same supplier for the COVID-19 clinical trial as the IPF/CC study? Who would be more at risk in either clinical trial by taking Ifenrpodil? Would it be IPF/CC patients or COVID-19 patients? Why would a supplier tell the company they won't risk negative exposure/feedback for a 20 patient IPF/CC clinical study and simultaneously risk exposure for 10 times the number of patients for COVID-19? Also, if we all know the drug Ifenprodil has a 45 year safety record what would suddenly be the catastrophic risk for the supplier to take based on safety issues? Does the CEO straight up lying to shareholders fall within the understanding of the meaning of "Vile"? I mean, when I make my claims I back them up with the ability to answer whomever questions about it. Not run off and hide until the smoke clears and start up another baseless rebuttal to someone else Due Diligence. I do my share of real Due Diligence.

M$

M$ Ball Marker :-D

1907 Proof Saint-Gaudens Gold Double Eagle
Ultra High Relief Lettered Edge
Value: $2,990,000